🤰 Brexanolone/Zuranolone Neurosteroid Mechanism Simulator

Pregnancy — Sustained High Allopregnanolone

Placeholder: progesterone climbs through pregnancy, driving allopregnanolone up.

• ~20×: Allopregnanolone rise in pregnancy (vs non-pregnant baseline)
• Progesterone: Primary precursor hormone (placental + ovarian source)
• GABA-A: Receptor target (main inhibitory receptor)
• High: Baseline mood stability (tonic inhibitory tone)

Placeholder heading — neurosteroid synthesis

Placeholder: allopregnanolone is synthesized from progesterone via 5α- and 3α-reductases.

Placeholder highlight — pregnancy neurosteroid levels dwarf normal cycling levels.

Placeholder heading — GABA-A tone

Placeholder: elevated allopregnanolone keeps GABA-A chloride channels open more often, calming neuronal excitability.

Placeholder heading — brain adaptation

Placeholder: neurons adapt receptor subunit composition to this sustained high-neurosteroid environment.

Childbirth — Abrupt Neurosteroid Withdrawal

Placeholder: delivery of the placenta ends the neurosteroid supply almost overnight.

• ~90%: Allopregnanolone drop (within days of delivery)
• ~1 in 7: Postpartum depression prevalence (birthing parents affected)
• Days 2–14: Symptom onset window (post-delivery)
• δ-subunit: Receptor subunit shift (altered GABA-A sensitivity)

Placeholder heading — the hormonal cliff

Placeholder: placental progesterone source disappears, so allopregnanolone falls far faster than it rose.

Placeholder highlight — the speed of the drop, not just its size, appears to matter clinically.

Placeholder heading — receptor mismatch

Placeholder: GABA-A receptors adapted to high neurosteroid tone are suddenly under-modulated.

Placeholder heading — susceptibility

Placeholder: some individuals are more sensitive to this withdrawal, driving postpartum mood destabilization.

Neurosteroid Drug Administered

Placeholder: brexanolone IV or zuranolone oral replace the lost modulatory signal.

• IV infusion: Brexanolone route (~60 hours continuous)
• Oral capsule: Zuranolone route (14-day course)
• Neurosteroid PAM: Drug class (GABA-A positive modulator)
• 2019 / 2023: FDA approval (brexanolone / zuranolone)

Placeholder heading — dosing regimens

Placeholder: brexanolone is a synthetic allopregnanolone given by slow IV titration over 60 hours.

Placeholder highlight — zuranolone brought this mechanism to a take-home oral pill.

Placeholder heading — pharmacokinetics

Placeholder: plasma levels build gradually, allowing the receptor system to re-equilibrate smoothly.

Placeholder heading — patient monitoring

Placeholder: brexanolone infusion requires monitored administration; zuranolone is outpatient.

GABA-A Positive Allosteric Modulation

Placeholder: drug molecules bind allosteric sites, opening the chloride channel wider.

• α/β interface: Binding site (transmembrane allosteric pocket)
• ↑ Open probability: Channel effect (and open duration)
• Positive allosteric: Modulation type (potentiates GABA response)
• Near baseline: Restored tone (GABAergic inhibition)

Placeholder heading — allosteric binding

Placeholder: neurosteroids dock at a site distinct from GABA itself, stabilizing the open channel state.

Placeholder highlight — this restores tone directly rather than boosting neurotransmitter supply.

Placeholder heading — chloride influx

Placeholder: wider, longer channel openings increase chloride influx, hyperpolarizing neurons.

Placeholder heading — network effect

Placeholder: restored inhibitory tone recalibrates circuits implicated in mood regulation.

Rapid Mood Improvement

Placeholder: symptom relief arrives in days by targeting the withdrawal directly.

• 2–3 days: Time to response (vs 4–6 weeks for SSRIs)
• ~70%: Brexanolone response rate (in pivotal trials)
• Neurosteroid withdrawal: Mechanism specificity (unique to postpartum)
• Sustained: Durability (after treatment course ends)

Placeholder heading — speed of relief

Placeholder: because the mechanism is restored directly, mood improvement is measured in days.

Placeholder highlight — this is markedly faster than standard antidepressant onset.

Placeholder heading — mechanism-matched therapy

Placeholder: treating the specific neurosteroid-withdrawal cause outperforms generic antidepressant approaches here.

Placeholder heading — clinical significance

Placeholder: this validated a new drug class specifically for postpartum depression.

Neurosteroid PAM therapies at a glance